natgillin/translations-raw huggingface dataset:
In this study, Blincyto was not compared with any other treatment.
U tom ispitivanju lijek Blincyto nije uspoređen ni s jednom drugom terapijom.
Each cycle of treatment is separated by a 2-week treatment-free interval.
Nakon svakog ciklusa liječenja slijedi razdoblje bez liječenja u trajanju od 2 tjedna.
A study in 70 children aged 1 year and above with Philadelphia-chromosome-negative B-precursor ALL found that in 33% of patients treatment with Blincyto led to a resolution of the disease.
U ispitivanju koje je uključivalo 70 djece s ALL-om prekursora B limfocita negativnih na Philadelphia kromosom u dobi od 1 godine i više, utvrđeno je da je liječenje lijekom Blincyto dovelo do povlačenja bolesti u 33 % bolesnika.
What benefits of Blincyto have been shown in studies?
Koje su koristi od lijeka Blincyto utvrđene u ispitivanjima?
Blincyto must not be given to breastfeeding women.
Blincyto se ne smije primjenjivati u dojilja.
The active substance in Blincyto, blinatumomab, is an antibody that has been designed to attach to a protein (CD19) found on B cells, including ALL cells.
Djelatna tvar u lijeku Blincyto, blinatumomab, protutijelo je koje je namijenjeno vezivanju na protein (CD19) koji se nalazi na B limfocitima, uključujući stanice akutne limfoblastične leukemije.
How is Blincyto used?
Kako se Blincyto primjenjuje?
Blincyto has been studied in one main study in 189 Philadelphia-chromosome-negative adults with Bprecursor ALL whose leukaemia had come back or had not improved with treatment.
U jednom glavnom ispitivanju lijek Blincyto ispitivan je na 189 odraslih osoba s ALL-om prekursora B‑lim focita negativnih na Philadelphia krom osom , u kojih se leukem ija vratila ili se liječenjem nije postiglo poboljšanje.
Blincyto is also used in adults who have been treated for B-precursor ALL and have minimal residual disease (which means that they still have some detectable cancer cells in their body).
Blincyto se primjenjuje i u odraslih osoba koje su bile podvrgnute liječenju ALL‑a prekursora B‑lim focita i im aju m inim alnu rezidualnu bolest (što znači da im se u tijelu još uvijek m ogu detektirati stanice raka).
For treatment of relapsed or refractory B-precursor ALL, the dose depends on the patient's bodyweight.
U liječenju relapsne ili refraktorne akutne limfoblastične leukemije prekursora B‑lim focita doza ovisi o bolesnikovoj tjelesnoj težini.
Blincyto is a medicine used to treat a blood cancer called B-precursor acute lymphoblastic leukaemia (ALL) in patients above 1 year of age when the cancer has come back (relapsed) or has not improved with previous treatment (refractory).
(ALL) prekursora B‑lim focita u bolesnika starijih od godinu dana u kojih se rak vratio (relaps) ili se prethodnim liječenjem nije postiglo poboljšanje (refraktoran).
Blincyto contains the active substance blinatumomab and is used on its own.
Blincyto sadrži djelatnu tvar blinatumomab te se primjenjuje kao monoterapija.
For the full list of side effects of Blincyto, see the package leaflet.
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Blincyto potražite u uputi o lijeku.
Blincyto therefore acts as a ‘bridge' bringing T cells and B cells together and causing the T cells to release substances that eventually kill the cancerous B cells.
Lijek Blincyto stoga djeluje kao „poveznica” koja spaja T‑lim focite i B‑ lim focite i potiče
Germany Glenmark Arzneimittel
Njemačka Glenmark Arzneimittel
Zydus France
Francuska Zydus France
Sweden Medical Valley Invest AB
Švedska Medical Valley Invest AB
Germany Hexal Aktiengesellschaft
Njemačka Hexal Aktiengesellschaft
Sanofi Aventis France
Francuska Sanofi Aventis France
Teva Nederland B.V.
Nizozemska Teva Nederland B.V.
Active Substance Strength Pharmaceutical Form
Jačina Farmaceutski oblik
Annex IB: Products for which the marketing authorisations are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation
Prilog I.B: Lijekovi za koje se preporučuje privremena obustava odobrenja za stavljanje lijeka u promet i zahtjevi za odobrenje za stavljanje lijeka u promet koji ne ispunjavaju kriterije za davanje odobrenja
Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for which bioequivalence vis-à-vis the EU reference medicinal product has been established
Prilog I.A: Lijekovi za koje se preporučuje zadržavanje odobrenja za stavljanje lijeka u promet i zahtjevi za odobrenje za stavljanje u promet lijekova za koje je utvrđena bioekvivalencija u odnosu na referentni lijek odobren u EU-u
amoxicillin mg
amoksicilin mg
Medipha Sante AMOXICILLINE MEDIPHA 1 g amoxicillin
Medipha Sante AMOXICILLINE MEDIPHA 1 g amoksicilin
Teva Sante
Francuska Teva Sante
Malacomp HEXAL junior atovaquone/ proguanil
Malacomp HEXAL junior atovakvon/ progvanil
Annex I List of nationally authorised medicinal products and marketing authorisation applications
Popis nacionalno odobrenih lijekova i zahtjeva za odobrenje za stavljanje lijeka u promet
Rasagiline Brown & Burk 1mg Tablets rasagiline
Rasagiline Brown & Burk 1mg Tablets razagilin
Medipha Sante
Francuska Medipha Sante
Rasagilin Micro Labs 1 mg Tabletten rasagiline
Rasagilin Micro Labs 1 mg Tabletten razagilin
Amoxicilina Brown amoxicillin
Amoxicilina Brown amoksicilin
EBASTINE ZENTIVA ebastine
EBASTINE ZENTIVA ebastin
Orodispersible tablet
Raspadljiva tableta za
EBASTINE BIOGARAN ebastine
EBASTINE BIOGARAN ebastin
Saquinavir Accord 500 mg plėvele dengtos tabletės saquinavir
Saquinavir Accord 500 mg plėvele dengtos tabletės sakvinavir
Celecoxib Medical Valley celecoxib
Celecoxib Medical Valley celekoksib
Amoxicilline Authou amoxicillin
Amoxicilline Authou amoksicilin
Sandoz Farmaceutica, S.A.
Španjolska Sandoz Farmaceutica, S.A.
Sweden Orifarm Generics A/S
Švedska Orifarm Generics A/S
Saquinavir Accord saquinavir
Saquinavir Accord sakvinavir
Germany Hormosan Pharma
Njemačka Hormosan Pharma
Celecoxib Hetero celecoxib
Celecoxib Hetero celekoksib
Celecoxib Brill Pharma 100 mg and 200 mg cápsulas duras celecoxib
Celecoxib Brill Pharma 100 mg and 200 mg cápsulas duras celekoksib
Saquinavir HEXAL 500 mg Filmtabletten saquinavir
Saquinavir HEXAL 500 mg Filmtabletten sakvinavir
10 mg Orodispersible tablet
10 mg Raspadljiva tableta za
Saquinavir Farmoz saquinavir
Saquinavir Farmoz sakvinavir
Pensa Pharma, S.A.U.
Španjolska Pensa Pharma, S.A.U.
Germany 1A Pharma GmbH
Njemačka 1A Pharma GmbH
Sweden Sandoz A/S
Švedska Sandoz A/S
Teva Pharma, S.L.U.
Španjolska Teva Pharma, S.L.U.
Saquinavir Accord 500 mg film-coated tablets saquinavir
Saquinavir Accord 500 mg film-coated tablets sakvinavir
Saquinavir saquinavir
Saquinavir sakvinavir
Sweden Mylan AB
Švedska Mylan AB
Germany Aristo Pharma GmbH
Njemačka Aristo Pharma GmbH
Biogaran
Francuska Biogaran
Amoxicillin Micro Labs 1000 mg amoxicillin
Amoxicillin Micro Labs 1000 mg amoksicilin
Celecoxib
celekoksib
Amoxicillin Micro Labs 750 mg amoxicillin
Amoxicillin Micro Labs 750 mg amoksicilin
Abacavir / Lamivudine abacavir/ lamivudine
Abacavir / Lamivudine abakavir/ lamivudin
25 mg Capsule, hard Oral use
25 mg Kapsula, tvrda Kroz usta
Amoxicillin Micro Labs 250 mg amoxicillin
Amoxicillin Micro Labs 250 mg amoksicilin
20 mg Capsule
20 mg Kapsula
Industria Química Y Farmacéutica VIR, S.A.
Španjolska Industria Química Y Farmacéutica
Irbesartan / Hydrochlorothiazide Micro Labs 300 mg /25 mg Filmtabletten irbesartan/ hydrochlorothiazide
Irbesartan / Hydrochlorothiazide Micro Labs 300 mg /25 mg Filmtabletten irbesartan/ hidroklorotiazid
Denmark Orifarm Generics A/S
Norveška Orifarm Generics A/S
60 mg Capsule
60 mg Kapsula
30 mg Capsule
30 mg Kapsula
Hydrochlorothiazide Micro Labs 150 mg/12.5 mg Filmtabletten irbesartan/ hydrochlorothiazide
Hydrochlorothiazide Micro Labs 150 mg/12.5 mg Filmtabletten irbesartan/ hidroklorotiazid
Amoxicillin Micro Labs 500 mg amoxicillin
Amoxicillin Micro Labs 500 mg amoksicilin
Celecoxib Glenmark 200 mg Hartkapseln celecoxib
Celecoxib Glenmark 200 mg Hartkapseln celekoksib
Celecoxib Glenmark 100 mg Hartkapseln celecoxib
Celecoxib Glenmark 100 mg Hartkapseln celekoksib
Celecoxib axcount 100 mg Hartkapseln celecoxib
Celecoxib axcount 100 mg Hartkapseln celekoksib
Celecoxib axcount 200 mg Hartkapseln celecoxib
Celecoxib axcount 200 mg Hartkapseln celekoksib
Hydrochlorothiazide Micro Labs 300 mg/12.5 mg Filmtabletten irbesartan/ hydrochlorothiazide
Hydrochlorothiazide Micro Labs 300 mg/12.5 mg Filmtabletten irbesartan/ hidroklorotiazid
Denmark ratiopharm GmBH
Danska ratiopharm GmBH
Etoricoxib PhaRes 120 mg Filmtabletten etoricoxib
Etoricoxib PhaRes 120 mg Filmtabletten etorikoksib
Finland ratiopharm GmbH
Finska ratiopharm GmbH
Mylan SAS
Francuska Mylan SAS
40 mg Capsule
40 mg Kapsula
Irbesartan/Hydrochlorot hiazide Brown & Burk 150mg/12.5mg Filmcoated tablets irbesartan/ hydrochlorothiazide
Irbesartan/Hydrochlorot hiazide Brown & Burk 150mg/12.5mg Filmcoated tablets irbesartan/ hidroklorotiazid
EBASTINE MYLAN ebastine
EBASTINE MYLAN ebastin
Venipharm
Francuska Venipharm
20 mg Capsule, hard Oral use
20 mg Kapsula, tvrda Kroz usta
200 mg Capsule, hard Oral use
200 mg Kapsula, tvrda Kroz usta
SAQUINAVIR SANDOZ saquinavir
SAQUINAVIR SANDOZ sakvinavir
60 mg Capsule, hard Oral use
60 mg Kapsula, tvrda Kroz usta
Etoricoxib PhaRes 30 mg Filmtabletten etoricoxib
Etoricoxib PhaRes 30 mg Filmtabletten etorikoksib
Germany ratiopharm GmbH
Njemačka ratiopharm GmbH
Etoricoxib PhaRes 90 mg Filmtabletten etoricoxib
Etoricoxib PhaRes 90 mg Filmtabletten etorikoksib
Etoricoxib PhaRes 60 mg Filmtabletten etoricoxib
Etoricoxib PhaRes 60 mg Filmtabletten etorikoksib
Irbesartan/Hydrochlorot hiazide Brown & Burk 300mg/12.5mg Filmcoated tablets irbesartan/ hydrochlorothiazide
Irbesartan/Hydrochlorot hiazide Brown & Burk 300mg/12.5mg Filmcoated tablets irbesartan/ hidroklorotiazid
Irbesartan/Hydrochlorot hiazide Brown & Burk 300mg/25mg Filmcoated tablets irbesartan/ hydrochlorothiazide
Irbesartan/Hydrochlorot hiazide Brown & Burk 300mg/25mg Filmcoated tablets irbesartan/ hidroklorotiazid
30 mg Capsule, hard Oral use
30 mg Kapsula, tvrda Kroz usta
Duloxetin-Hormosan 30 mg magensaftresistente Hartkapseln duloxetine
Duloxetin-Hormosan 30 mg magensaftresistente Hartkapseln duloksetin
Duloxetine Lupin 60mg GR capsules duloxetine
Duloxetine Lupin 60mg GR capsules duloksetin
100 mg Capsule, hard Oral use
100 mg Kapsula, tvrda Kroz usta
Duloxetin-Hormosan 20 mg magensaftresistente Hartkapseln duloxetine
Duloxetin-Hormosan 20 mg magensaftresistente Hartkapseln duloksetin
40 mg Capsule, hard Oral use
40 mg Kapsula, tvrda Kroz usta
Duloxetin-Hormosan 60 mg magensaftresistente Hartkapseln duloxetine
Duloxetin-Hormosan 60 mg magensaftresistente Hartkapseln duloksetin
Duloxetin-Hormosan 40 mg magensaftresistente Hartkapseln duloxetine
Duloxetin-Hormosan 40 mg magensaftresistente Hartkapseln duloksetin
Duloxetine Lupin 20mg GR capsules duloxetine
Duloxetine Lupin 20mg GR capsules duloksetin
Duloxetine Lupin 30mg GR capsules duloxetine
Duloxetine Lupin 30mg GR capsules duloksetin
Duloxetine Lupin 40mg GR capsules duloxetine
Duloxetine Lupin 40mg GR capsules duloksetin
Sandoz
Francuska Sandoz
ebastine
ebastin
saquinavir
sakvinavir
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states for all authorised methadone medicinal products for oral use containing povidone
Popis naziva, farmaceutskog(ih) oblika, jačine(a) lijek(ov)a, put(ev)a primjene, nositelj(a) odobrenja u državama članicama
Essex RM3 8UG United Kingdom
Essex RM3 8UG
Martindale Pharmaceuticals Ltd.
Velika Britanija Martindale Pharmaceuticals Ltd.
Bampton
Bampton Road
The review of HPV vaccines was initiated on 9 July 2015 by the European Commission at the request of Denmark, under Article 20 of Regulation (EC) No 726/2004.
Pregled cjepiva protiv HPV-a započela je Europska komisija 9. srpnja 2015. godine na zahtjev Danske u skladu s člankom 20. Uredbe (EZ) br. 726/2004.
• Patients or families who have any concerns should consult their healthcare professional.
• Bolesnici ili obitelji koje imaju bilo kakve nedoumice trebaju se obratiti svojem zdravstvenom djelatniku.
Following their approval, the vaccines have been introduced in national immunisation programs in many countries.
Nakon njihova odobrenja cjepiva su uvedena u nacionalne programe imunizacije u brojnim zemljama.
The final stage of the review procedure was the adoption by the European Commission of a legally binding decision applicable in all EU Member States on 12/01/2016.
Završna faza postupka pregleda bilo je donošenje pravno obvezujuće odluke Europske komisije primjenjive u svim državama članicama EU-a dana 12./01./2016. godine.
The assessment report containing the evidence supporting the Agency's review is available on EMA's website.
Izvješće o ocjeni koje sadrži dokaze kojima se podupire Agencijin pregled dostupno je na EMA-inoj internetskoj stranici.
Gardasil 9 (approved in June 2015) is used similarly but contains antigens for 9 types of the virus (types 6, 11, 16, 18, 31, 33, 45, 52 and 58).
Gardasil 9 (odobren u lipnju 2015. godine) primjenjuje se na sličan način, no sadrži antigene za 9 tipova virusa (tipove 6, 11, 16, 18, 31, 33, 45, 52 i 58).
It contains antigens for types 16 and 18 of the virus.
Sadrži antigene za tipove virusa 16 i 18.
The safety of these vaccines, as with all medicines, will continue to be carefully monitored and will take into account any future new evidence of side effects that becomes available.
Sigurnost tih cjepiva, kao i u slučaju svih lijekova, i dalje će se pažljivo nadzirati te će se u obzir uzimati svi novi dokazi o nuspojavama koji postani dostupni u budućnosti.
In some patients they can severely affect the quality of life.
U pojedinih bolesnika ta stanja mogu ozbiljno utjecati na kvalitetu života.
The Agency also consulted a group of experts in these syndromes and in neurology, cardiology and pharmacoepidemiology.
Agencija se također posavjetovala sa skupinom stručnjaka u području tih sindroma i neurologije, kardiologije te farmakoepidemiologije.
• CRPS and POTS are difficult to diagnose.
• KRBS i SPOT teško je dijagnosticirati.
The CHMP's position was passed to the European Commission which endorsed it and issued a legally binding decision.
Stajalište CHMP-a poslano je Europskoj komisiji koja ga je potvrdila i izdala konačnu pravno obvezujuću odluku.
It contains antigens (proteins that help product antibodies) against 4 types of HPV (types 6, 11, 16 and 18).
Sadrži antigene (proteine koji pomažu u proizvodnji protutijela) protiv četiri tipa HPV-a (tipa 6, 11, 16 i 18).
It is estimated that more than 63 million girls and women worldwide have been vaccinated with Gardasil/Silgard and more than 19 million with Cervarix.
Procjenjuje se da je više od 63 milijuna djevojaka i žena diljem svijeta cijepljeno cjepivom Gardasil/Silgard, a više od 19 milijuna cjepivom Cervarix.
HPV vaccines are available in the European Union under the names Gardasil/Silgard, Gardasil 9, and Cervarix.
Cjepiva protiv HPV-a dostupna su u Europskoj uniji pod nazivima Gardasil/Silgard, Gardasil 9 i Cervarix.
HPV vaccines are expected to prevent many cases of such conditions.
Očekuje se da će cjepiva protiv HPV-a spriječiti brojne slučajeve tih stanja.
It is recognised that in some affected girls these syndromes can be long lasting and severely impact quality of life.
Utvrđeno je da u pojedinih djevojaka u kojih su se javili ti sindromi oni mogu biti dugotrajni i ozbiljno utjecati na kvalitetu života.
On 19 November EMA completed its review of the evidence surrounding reports of two syndromes, complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS) in young women given human papillomavirus (HPV) vaccines.
Dana 19. studenoga EMA je dovršila pregled dokaza koji se odnose na prijavljene slučajeve dvaju sindroma, kompleksnog regionalnog bolnog sindroma (KRBS) i sindroma posturalne ortostatske tahikardije (SPOT) u mladih žena koje cijepljene protiv humanog papiloma virusa (HPV).
It is usually confined to a single limb.
Najčešće se pojavljuje samo u jednom udu.
The findings of the PRAC were passed to the Agency's Committee for Medicinal Products for Human Use (CHMP), along with further representations from patient groups.
Rezultati PRAC-a poslani su Agencijinu Odboru za lijekove za humanu uporabu (CHMP) zajedno s daljnjim prikazima iz skupina bolesnika.
The review recognised that more than 80 million girls and women worldwide have now received these vaccines, and in some European countries they have been given to 90% of the age group recommended for vaccination.
U pregledu je utvrđeno da je više od 80 milijuna djevojčica i žena diljem svijeta primilo ova cjepiva, a u nekim je europskim zemljama među njima cijepljeno 90 % pripadnica dobne skupine za koju se preporučuje cijepljenje.
The syndromes are recognised to occur in the general population, including adolescents, regardless of vaccination.
Utvrđeno je da se sindromi javljaju među općim stanovništvom uključujući adolescente, neovisno o cijepljenju.
The PRAC recommendations were sent to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency's final opinion.
Preporuke PRAC-a poslane su Odboru za lijekove za humanu uporabu (CHMP) odgovornom za pitanja koja se odnose na lijekove za humanu uporabu, koji je usvojio Agencijino konačno mišljenje.
In line with its initial recommendations, EMA confirmed that the evidence does not support a causal link between the vaccines (Cervarix, Gardasil/Silgard and Gardasil 9) and development of CRPS or POTS.
U skladu sa svojim početnim preporukama EMA je potvrdila da dokazi ne podupiru uzročnu vezu između cjepiva (Cervarixa, Gardasila/Silgarda i Gardasila 9) i razvoja KRBSa ili SPOT-a.
The above recommendations are based on analyses of clinical trial and post-marketing data and included review of published literature, spontaneous reports of suspected adverse effects, reports submitted by Member States as well as information from other countries, and information submitted voluntarily by the public.
Prethodne preporuke temelje se na analizama kliničkog ispitivanja i podacima nakon izdavanja odobrenja za stavljanje cjepiva u promet te su uključivale pregled objavljene literature, spontane prijavljene slučajeve sumnje na negativne učinke, izvješća koja su predale države članice te informacije iz ostalih zemalja i informacije koje je javnost dobrovoljno predala.
It therefore did not recommend any changes to the terms of licensing or the product information for these medicines.
Stoga nije preporučio izmjene uvjeta izdavanja odobrenja ili informacija o proizvodu za te lijekove.
The review was first carried out by the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee responsible for the evaluation of safety issues for human medicines, which made a set of recommendations.
Pregled je prvi put proveo Odbor za procjenu rizika u području farmakovigilancije (PRAC), odbor odgovoran za procjenu sigurnosnih pitanja u pogledu lijekova za humanu uporabu, koji je iznio niz preporuka.
Reports after HPV vaccination consistent with what would be expected in this age group
Prijavljeni slučajevi nakon cijepljenja protiv HPV-a u skladu su s očekivanim u ovoj dobnoj skupini
Symptoms often overlap with other conditions such as chronic fatigue syndrome.
Simptomi se često preklapaju s ostalim stanjima kao što je sindrom kroničnog umora.
Given that many reports have features of chronic fatigue syndrome, evidence including a large published study1 that showed no link between chronic fatigue syndrome and HPV vaccines was also considered relevant.
Budući da su mnogi prijavljeni slučajevi imali značajke sindroma kroničnog umora, dokazi uključujući veliku objavljenu studiju1 kojima se pokazalo da ne postoji veza između sindroma kroničnog umora i cjepiva protiv HPV-a također su se smatrali važnima.
The Agency's review included published research, data from clinical trials and reports of suspected side effects from patients and healthcare professionals, as well as data supplied by Member States.
Agencijin pregled uključivao je objavljeno istraživanje, podatke iz kliničkih ispitivanja i prijavljene slučajeve sumnje na nuspojave bolesnika i zdravstvenih djelatnika te podatke koje su dostavile države članice.
• HPV (human papillomavirus) is a major cause of cancer of the cervix (neck of the womb) and some other cancers, as well as other conditions such as genital warts.
• HPV (humani papiloma virus) glavni je uzrok raka cerviksa (grlića maternice) i pojedinih ostalih vrsta raka te drugih stanja kao što su genitalne bradavice.
The review noted that some symptoms of CRPS and POTS may overlap with chronic fatigue syndrome (CFS, also known as myalgic encephalomyelitis or ME).
Pregledom je uočeno da se neki simptomi KRBS-a i SPOT-a mogu preklapati sa sindromom kroničnog umora (SKU, također poznat kao mijalgični encefalomijelitis ili ME).
Results of a large published study that showed no link between HPV vaccine and CFS were therefore particularly relevant.
Stoga su rezultati velike objavljene studije kojom se nije pokazala veza između cjepiva protiv HPV-a i SKU-a bili od osobite važnosti.
• A careful review looking at the available evidence has concluded that the occurrence of CRPS and POTS in vaccinated girls is no higher than would be expected in girls in the general population (around 150 cases of CRPS and at least 150 of POTS per million each year), and that there is no evidence that the vaccines can trigger these syndromes.
• Pažljivim pregledom u kojem su se istraživali dostupni dokazi zaključeno je da stopa pojave KRBSa i SPOT-a u cijepljenih djevojaka nije veća od očekivane stope u djevojaka među općim stanovništvom (oko 150 slučajeva KRBS-a i najmanje 150 slučajeva SPOT-a na njih milijun godišnje) te da ne postoje dokazi o tome da cjepiva mogu potaknuti pojavu tih sindroma.
• Patients with POTS (postural orthostatic tachycardia syndrome) typically show abnormal increases in heart rate on standing, without orthostatic hypotension.
• U bolesnika u kojih se javlja SPOT (sindrom posturalne ortostatske tahikardije) obično je prisutno abnormalno povećanje brzine otkucaja srca pri stajanju, bez ortostatske hipotenzije.
Symptoms of CRPS and POTS may overlap with other conditions, making diagnosis difficult in both the general population and vaccinated individuals.
Simptomi KRBS-a i SPOT-a mogu se preklapati s drugim stanjima, što otežava dijagnozu kod općeg stanovništva i cijepljenih pojedinaca.
• Routine surveillance of suspected adverse reaction reports has raised questions on the potential association between the use of HPV vaccines and two syndromes, CRPS and POTS.
• Rutinski nadzor prijava sumnji na nuspojave doveo je do pitanja o mogućoj povezanosti između primjene cjepiva protiv HPV-a i dvaju sindroma, KRBS-a i SPOT-a.
The review took into account cases not reported as CRPS and POTS but with signs and symptoms suggestive of these conditions.
U pregledu su uzeti u obzir slučajevi koji nisu prijavljeni kao KRBS ili SPOT, ali u njima su prisutni znakovi i simptomi koji upućuju na ta stanja.
• CRPS (chronic regional pain syndrome) is defined as continuing pain that is disproportionate to the inciting event (typically an episode of trauma or limb immobilisation), and is associated with sensory, sudomotor, motor and dystrophic changes.
• KRBS (kompleksni regionalni bolni sindrom) definira se kao stalna bol koja je nije razmjerna uzročnom događaju (obično traumi ili imobilizaciji uda), a povezana je s osjetilnim, sudomotornim, motornim i distrofičnim promjenama.
The benefits of HPV vaccines continue to outweigh their risks.
Koristi cjepiva protiv HPV-a i dalje nadmašuju s njima povezane rizike.
The benefits of HPV vaccines therefore continue to outweigh the known side effects.
Stoga koristi cjepiva protiv HPV-a i dalje nadmašuju s njima povezane poznate nuspojave.